BioSpace News Archive

Curium, the world’s leading nuclear medicine company, announced the expansion of its North America Headquarters in St. Louis.

Aerovate Therapeutics, Inc. today announced that Company management will participate in a panel discussion at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, at 10:30 a.m. ET.

ViaDerma, Inc. is pleased to provide an update on current business activities.

InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report fourth quarter and full-year 2022 financial results on Thursday, March 30, 2023, before the financial markets open.

Avenue Therapeutics, Inc. today announced that it has entered into an exclusive license agreement with AnnJi Pharmaceutical Co., Ltd. (“AnnJi”), a Taiwanese clinical-stage drug company, for AJ201, a first-in-class clinical asset currently in a Phase 1b/2a study in the U.S. for the treatment of spinal and bulbar muscular atrophy (“SBMA”), also known as Kennedy’s Disease.

Colorcon, Inc. announces that it has completed the acquisition of Airnov Healthcare Packaging, Inc. from Arsenal Capital Partners.

DarioHealth Corp. announced it would release its financial results for the fourth quarter and year ended December 31, 2022, on Thursday, March 9, 2023, before market opens and will host a conference call and webcast at 8:30 am Eastern Time.

Corbus Pharmaceuticals Holdings, Inc. today announced that Yuval Cohen , Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Oppenheimer 33rd Annual Healthcare Conference.

Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the publication of a study in the journal Viruses, validating the use of SeptiCyte® RAPID as a tool to measure disease severity in COVID-19 patients, in comparison to a reference method based on chest computed tomography (CT) imaging.

Santhera Pharmaceuticals announces that it has submitted a marketing authorization application to the UK Medicines and Healthcare products Regulatory Agency for vamorolone for the treatment of Duchenne muscular dystrophy.